Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy

Kenta Nio, Shuji Arita, Taichi Isobe, Hitoshi Kusaba, Kenichi Kouhashi, Tatsuhiro Kajitani, Shingo Tamura, Gen Hirano, Kenji Mitsugi, Akitaka Makiyama, Taito Esaki, hiroshi ariyama, Yoshinao Oda, Koichi Akashi, Eishi Baba

研究成果: ジャーナルへの寄稿記事

8 引用 (Scopus)

抄録

Purpose: Extrapulmonary neuroendocrine carcinomas (EPNEC) are rarely observed and are associated with poor outcomes. Based on the clinicopathological similarity, treatment used for small cell lung carcinoma has also been employed for EPNEC, but the response to such therapy has not been well examined. The goal of this study was to investigate amrubicin (AMR) monotherapy as a salvage therapy for EPNEC arising from digestive organs. Methods: Patients with EPNEC of the digestive organs who had prior platinum-based chemotherapy and were subsequently treated with AMR between July 2005 and December 2013 at any one of four institutions were retrospectively examined to characterize the safety and efficacy of AMR. Results: Thirteen patients (ten males, three females; median age 64 years) were examined. Primary cancer sites included stomach (n = 6), rectum (n = 3), esophagus (n = 2), liver (n = 1) and pancreas (n = 1). Prior irinotecan- and etoposide-containing chemotherapies were used in ten and six patients, respectively. Median initial dose of AMR was 40 mg/m2/day for three consecutive days, and median of treatment cycles was 4 (range 1-9). The objective response rate (ORR) was 38.5 %. Median progression-free survival (PFS) and overall survival (OS) were 107 (range 22-275) and 215 days (range 71-535), respectively. Common severe adverse events (grade 3/4) were neutropenia (84.6 %) and febrile neutropenia (30.8 %). Patient with longer platinum-free interval (>90 days) exhibited longer PFS and OS than those with shorter platinum-free interval (190 vs. 63 days and 348 vs. 145 days, respectively). Conclusions: AMR showed evidence of clinical activity and safety when used for the treatment of EPNEC. It might be especially useful for populations with sensitive relapse.

元の言語英語
ページ(範囲)829-835
ページ数7
ジャーナルCancer Chemotherapy and Pharmacology
75
発行部数4
DOI
出版物ステータス出版済み - 1 1 2015

Fingerprint

Neuroendocrine Carcinoma
Chemotherapy
Platinum
Drug Therapy
irinotecan
Disease-Free Survival
Safety
Salvaging
Salvage Therapy
Febrile Neutropenia
Survival
Small Cell Lung Carcinoma
Vulnerable Populations
Etoposide
Therapeutics
Neutropenia
Rectum
Liver
Esophagus
Pancreas

All Science Journal Classification (ASJC) codes

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

これを引用

Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy. / Nio, Kenta; Arita, Shuji; Isobe, Taichi; Kusaba, Hitoshi; Kouhashi, Kenichi; Kajitani, Tatsuhiro; Tamura, Shingo; Hirano, Gen; Mitsugi, Kenji; Makiyama, Akitaka; Esaki, Taito; ariyama, hiroshi; Oda, Yoshinao; Akashi, Koichi; Baba, Eishi.

:: Cancer Chemotherapy and Pharmacology, 巻 75, 番号 4, 01.01.2015, p. 829-835.

研究成果: ジャーナルへの寄稿記事

Nio, Kenta ; Arita, Shuji ; Isobe, Taichi ; Kusaba, Hitoshi ; Kouhashi, Kenichi ; Kajitani, Tatsuhiro ; Tamura, Shingo ; Hirano, Gen ; Mitsugi, Kenji ; Makiyama, Akitaka ; Esaki, Taito ; ariyama, hiroshi ; Oda, Yoshinao ; Akashi, Koichi ; Baba, Eishi. / Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy. :: Cancer Chemotherapy and Pharmacology. 2015 ; 巻 75, 番号 4. pp. 829-835.
@article{41e4b4d457264128a49cc1b26ebee2dd,
title = "Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy",
abstract = "Purpose: Extrapulmonary neuroendocrine carcinomas (EPNEC) are rarely observed and are associated with poor outcomes. Based on the clinicopathological similarity, treatment used for small cell lung carcinoma has also been employed for EPNEC, but the response to such therapy has not been well examined. The goal of this study was to investigate amrubicin (AMR) monotherapy as a salvage therapy for EPNEC arising from digestive organs. Methods: Patients with EPNEC of the digestive organs who had prior platinum-based chemotherapy and were subsequently treated with AMR between July 2005 and December 2013 at any one of four institutions were retrospectively examined to characterize the safety and efficacy of AMR. Results: Thirteen patients (ten males, three females; median age 64 years) were examined. Primary cancer sites included stomach (n = 6), rectum (n = 3), esophagus (n = 2), liver (n = 1) and pancreas (n = 1). Prior irinotecan- and etoposide-containing chemotherapies were used in ten and six patients, respectively. Median initial dose of AMR was 40 mg/m2/day for three consecutive days, and median of treatment cycles was 4 (range 1-9). The objective response rate (ORR) was 38.5 {\%}. Median progression-free survival (PFS) and overall survival (OS) were 107 (range 22-275) and 215 days (range 71-535), respectively. Common severe adverse events (grade 3/4) were neutropenia (84.6 {\%}) and febrile neutropenia (30.8 {\%}). Patient with longer platinum-free interval (>90 days) exhibited longer PFS and OS than those with shorter platinum-free interval (190 vs. 63 days and 348 vs. 145 days, respectively). Conclusions: AMR showed evidence of clinical activity and safety when used for the treatment of EPNEC. It might be especially useful for populations with sensitive relapse.",
author = "Kenta Nio and Shuji Arita and Taichi Isobe and Hitoshi Kusaba and Kenichi Kouhashi and Tatsuhiro Kajitani and Shingo Tamura and Gen Hirano and Kenji Mitsugi and Akitaka Makiyama and Taito Esaki and hiroshi ariyama and Yoshinao Oda and Koichi Akashi and Eishi Baba",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/s00280-015-2706-y",
language = "English",
volume = "75",
pages = "829--835",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy

AU - Nio, Kenta

AU - Arita, Shuji

AU - Isobe, Taichi

AU - Kusaba, Hitoshi

AU - Kouhashi, Kenichi

AU - Kajitani, Tatsuhiro

AU - Tamura, Shingo

AU - Hirano, Gen

AU - Mitsugi, Kenji

AU - Makiyama, Akitaka

AU - Esaki, Taito

AU - ariyama, hiroshi

AU - Oda, Yoshinao

AU - Akashi, Koichi

AU - Baba, Eishi

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Purpose: Extrapulmonary neuroendocrine carcinomas (EPNEC) are rarely observed and are associated with poor outcomes. Based on the clinicopathological similarity, treatment used for small cell lung carcinoma has also been employed for EPNEC, but the response to such therapy has not been well examined. The goal of this study was to investigate amrubicin (AMR) monotherapy as a salvage therapy for EPNEC arising from digestive organs. Methods: Patients with EPNEC of the digestive organs who had prior platinum-based chemotherapy and were subsequently treated with AMR between July 2005 and December 2013 at any one of four institutions were retrospectively examined to characterize the safety and efficacy of AMR. Results: Thirteen patients (ten males, three females; median age 64 years) were examined. Primary cancer sites included stomach (n = 6), rectum (n = 3), esophagus (n = 2), liver (n = 1) and pancreas (n = 1). Prior irinotecan- and etoposide-containing chemotherapies were used in ten and six patients, respectively. Median initial dose of AMR was 40 mg/m2/day for three consecutive days, and median of treatment cycles was 4 (range 1-9). The objective response rate (ORR) was 38.5 %. Median progression-free survival (PFS) and overall survival (OS) were 107 (range 22-275) and 215 days (range 71-535), respectively. Common severe adverse events (grade 3/4) were neutropenia (84.6 %) and febrile neutropenia (30.8 %). Patient with longer platinum-free interval (>90 days) exhibited longer PFS and OS than those with shorter platinum-free interval (190 vs. 63 days and 348 vs. 145 days, respectively). Conclusions: AMR showed evidence of clinical activity and safety when used for the treatment of EPNEC. It might be especially useful for populations with sensitive relapse.

AB - Purpose: Extrapulmonary neuroendocrine carcinomas (EPNEC) are rarely observed and are associated with poor outcomes. Based on the clinicopathological similarity, treatment used for small cell lung carcinoma has also been employed for EPNEC, but the response to such therapy has not been well examined. The goal of this study was to investigate amrubicin (AMR) monotherapy as a salvage therapy for EPNEC arising from digestive organs. Methods: Patients with EPNEC of the digestive organs who had prior platinum-based chemotherapy and were subsequently treated with AMR between July 2005 and December 2013 at any one of four institutions were retrospectively examined to characterize the safety and efficacy of AMR. Results: Thirteen patients (ten males, three females; median age 64 years) were examined. Primary cancer sites included stomach (n = 6), rectum (n = 3), esophagus (n = 2), liver (n = 1) and pancreas (n = 1). Prior irinotecan- and etoposide-containing chemotherapies were used in ten and six patients, respectively. Median initial dose of AMR was 40 mg/m2/day for three consecutive days, and median of treatment cycles was 4 (range 1-9). The objective response rate (ORR) was 38.5 %. Median progression-free survival (PFS) and overall survival (OS) were 107 (range 22-275) and 215 days (range 71-535), respectively. Common severe adverse events (grade 3/4) were neutropenia (84.6 %) and febrile neutropenia (30.8 %). Patient with longer platinum-free interval (>90 days) exhibited longer PFS and OS than those with shorter platinum-free interval (190 vs. 63 days and 348 vs. 145 days, respectively). Conclusions: AMR showed evidence of clinical activity and safety when used for the treatment of EPNEC. It might be especially useful for populations with sensitive relapse.

UR - http://www.scopus.com/inward/record.url?scp=84925515955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925515955&partnerID=8YFLogxK

U2 - 10.1007/s00280-015-2706-y

DO - 10.1007/s00280-015-2706-y

M3 - Article

C2 - 25702050

AN - SCOPUS:84925515955

VL - 75

SP - 829

EP - 835

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 4

ER -